Brokerages Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $5.25

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have earned a consensus rating of “Hold” from the eight analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $5.25.

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Wells Fargo & Company boosted their target price on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Maravai LifeSciences Trading Down 3.1%

Shares of NASDAQ:MRVI opened at $3.71 on Wednesday. The company’s 50-day moving average price is $3.61 and its two-hundred day moving average price is $3.07. Maravai LifeSciences has a one year low of $1.66 and a one year high of $6.05. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56. The stock has a market capitalization of $948.68 million, a PE ratio of -4.42 and a beta of 0.33.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The company had revenue of $41.63 million during the quarter, compared to analyst estimates of $49.02 million. On average, equities analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Insider Transactions at Maravai LifeSciences

In other news, Director Gregory T. Lucier bought 51,472 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $190,446.40. Following the purchase, the director owned 106,595 shares of the company’s stock, valued at approximately $394,401.50. This trade represents a 93.38% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bernd Brust purchased 216,212 shares of Maravai LifeSciences stock in a transaction that occurred on Thursday, November 13th. The shares were acquired at an average price of $3.25 per share, with a total value of $702,689.00. Following the acquisition, the chief executive officer directly owned 466,771 shares of the company’s stock, valued at $1,517,005.75. This trade represents a 86.29% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 566,771 shares of company stock valued at $1,880,244. Insiders own 2.11% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sprott Inc. bought a new position in shares of Maravai LifeSciences during the 3rd quarter worth approximately $29,000. Callan Family Office LLC bought a new stake in Maravai LifeSciences in the 2nd quarter valued at $25,000. Ethic Inc. acquired a new stake in Maravai LifeSciences during the 2nd quarter valued at $26,000. Quantessence Capital LLC bought a new position in Maravai LifeSciences during the third quarter worth $31,000. Finally, Abel Hall LLC acquired a new position in shares of Maravai LifeSciences in the third quarter valued at $33,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.